Floatz Rating
C38/100
Confidence
Indicative
Sponsor
Mclean Hospital
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04075435CT.gov Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anxiety Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Low Thc (this asset) | Mclean Hospital | Early P1 | C · 38 |
| Risperidone | Tianjin Medical University General Hospital | P4 | BBB |
| Sertraline | Holland Bloorview Kids Rehabilitation Hospital | P4 | BBB |
| Olanzapine | Tianjin Medical University General Hospital | P4 | BBB |
| Fluoxetine | Hannover Medical School | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Theresa Jacob, PhD, MPH | P4 | BBB |
| Escitalopram | Wake Forest University Health Sciences | P4 | BB |
| Midazolam | Theresa Jacob, PhD, MPH | P4 | BB |
| Amitryptaline | University of Ghana Medical School | P4 | BB |
+42 more in the Anxiety Disorder cohort
Other indications for Low Thc
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Low Thc in Anxiety Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/low-thc-anxiety-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →